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Variable Laser (N ¼ 37) No Laser (N ¼ 81) P value
Age, years 73  11 69  11 0.06
Male (%) 18 (49) 41 (51) 0.9
ABI 0.70  0.22 0.65  0.18 0.3
TBI 0.33  0.21 0.37  0.18 0.4
Total lesion length, mm 185  118 114  106 0.001
Reference vessel
diameter, mm
5.3  0.6 5.3  0.7 0.9
TASC II C/D 21 (64) 25 (35) 0.007
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMangiography or computed tomography. We compared the outcomes of SFA angio-
plasty with versus without combined BTKI.
Results: More limbs treated with BTKI showed absence of any run-off vessel before
angioplasty (56% vs 19%, p< 0.001). Other baseline characteristics were similar. SFA
lesion length did not differ between the limbs with and without BTKI (226101 vs
24872 mm, p¼0.214). At 1-year follow-up, overall mortality rate was 14% and 7%
for patients with and without BTKI, retrospectively (p¼0.235). There was no major
amputation in both groups. Unexpected minor amputation rate was 11% and 3%,
respectively (p¼0.120). Target vessel revascularization rate for limbs with BTKI was
18% versus 11% for limbs without BTKI (p¼0.292). Kaplan-Meier analysis showed
limbs with BTKI have a lower 1 year patency rate (log rank p¼0.032) than those
without BTKI.Tosaka Class 0.001
1 5 (14) 32 (40)
2 12 (32) 32 (40)
3 20 (54) 17 (20)Conclusions: BTKI showed no beneﬁcial impact on outcomes of SFA lesions after
angioplasty in limbs with poor run-off vessels.
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Background: Femoropoliteal in-stent restenosis (FP-ISR) is associated with high
rates of recurrent stenosis and stent occlusion after endovascular therapy. Laser
atherectomy provides neointimal debulking and possible subsequent improved
patency in the treatment of FP-ISR.
Methods: All cases of FP-ISR treated between 2006-2013 were retrospectively
identiﬁed. FP-ISR was divided into three angiographic classes: Class I ( 50 mm
length); Class II (>50 mm length); and Class III (in-stent occlusion). Baseline de-
mographics and lesion angiographic characteristics were compared between groups.
Recurrent stenosis, as assessed by duplex ultrasound, was determined routinely at 3-4
month intervals up to 24 months post-intervention.
Results: One hundred and eighteen patients underwent endovascular treatment of
FP-ISR. Thirty-seven patients (31%) were treated with laser atherectomy and balloon
angioplasty, while 81 patients were treated with balloon angioplasty. Patients treated
with laser atherectomy had longer mean lesion length of FP-ISR (185 mm vs. 116
mm, p¼0.001) and were more likely to have Class III ISR (54% vs. 20%, p¼0.001)
and TASC C/D lesions (64% vs. 35%, p¼0.007). Procedural success was achieved in
100% of laser-assisted cases and 98% of non-laser-assisted cases. Complication rates
were low, with four distal embolizations in the laser group and one in the non-laser
group (p¼0.01). There was no association between laser atherectomy and rates of
recurrent stenosis or occlusion for patients with Class I or Class II FP-ISR. In com-
parison, patients with Class III FP-ISR treated with laser atherectomy were less likely
to develop recurrent stenosis at one year (54% vs. 91%, p¼0.05) and two year (69%
vs. 100%, p¼0.05) follow-up.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/IliaConclusions: Laser atherectomy with adjunctive balloon angioplasty may be asso-
ciated with improved patency when used to treat complex FP-ISR, including longer
lesions and in-stent occlusions.
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Background: Previous studies revealed that diabetes mellitus is associated with the
early restenosis after nitinol stenting in the femoropopliteal (FP) disease. The purpose
of this study is to investigate the advantage of endovascular therapy (EVT) with drug
eluting stents (DES) for FP lesions in diabetic patients.
Methods: This is a single center, retrospective observational study. Between July
2008 and April 2013, 101 FP lesions in 76 diabetic patients were treated with bare
metal stents (BMS group). 52 FP lesions in 42 diabetic patients were treated with
Zilver PTX paclitaxel-eluting nitinol stents (DES group). We evaluate the clinical
outcomes at 8 months after EVT. Stent patency was assessed by either duplex ul-
trasound or angiography.
Results: Follow-up rate at 8 months were 96% (73 patients) in BMS group and 93%
(39 patients) in DES group. Primary patency rates at 8 months were 92.9% with BMS
and 89.6% with DES . (p¼0.50) Major adverse limb events (MALE) occurred in 3
limbs with BMS and 4 limbs with DES in 8 months after stenting. (p¼0.14) Survival
rate at 8 months were similar. (95.9% vs 89.4% p¼0.21) Event-free survival rate
(freedom from all death, MALE and restenosis) were not signiﬁcant different. (87.7%
vs 76.9% p¼0.15).
Conclusions: FP stenting for diabetic patients with DES offers no signiﬁcant
advantage over BMS in middle- term clinical outcome.
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Background: It has not been reported that intravascular ultrasound (IVUS) ﬁndings
correlate with drug eluting stent (DES) restenosis after endovascular therapy for
femoropopliteal lesions. So we investigated that in this study.
Methods: This was a single center non-randomized retrospective study. From April
2012 to March 2013, a total of 71 consecutive de novo femoropopliteal lesions in
patients who underwent intravascular ultrasound (IVUS) after DES implantation were
included. The mean follow-up period was 124 months. In-stent restenosis (ISR) was
deﬁned as a peak systolic velocity ratio >2.4 on duplex ultrasonography or >75%
stenosis on angiography. ISR were detected in 14 lesions (19.7%). Subjects were
classiﬁed into two groups: the patients with ISR (ISR group, 14 lesions, 12 patients)
and without ISR (non-ISR group, 57 lesions, 49 patients). We compared post-pro-
cedural IVUS ﬁndings between two groups.
Results: For baseline patients and lesion characteristics, the percentage of women was
higher in ISR group than non-ISR group (83.3% vs. 20.4%, p< 0.05). There were no
signiﬁcant differences between two groups in diabetes mellitus (33.3% vs. 32.7%,
p¼0.96), hemodialysis (8.3% vs. 26.5%, p¼0.18), TASC II classiﬁed C or D lesions
(28.6% vs. 35.1%, p¼0.64), and critical limb ischemia (33.3% vs. 53.0%, p¼0.22).c and SFA B159
